Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Optimized Glycemic Control in Heart Failure Patients With DM2:"Effect on Left Ventricular Function and Skeletal Muscle" (HFDM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01213784
Recruitment Status : Completed
First Posted : October 4, 2010
Last Update Posted : March 6, 2015
The Danish Diabetes Association
Information provided by (Responsible Party):
University of Aarhus

Brief Summary:

The investigators wish to investigate wether a more strict diabetic control improves cardiac function, muscle strength, exercise capacity and decreases symptoms.

The investigators hypothesis is that improving the glycemic control in suboptimized diabetics with heart failure will improve cardiac performance, muscle strength, exercise capacity and decrease symptoms.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Heart Failure Other: all antidiabetic drugs will be appliable Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Optimized Glycemic Control in Type 2 Diabetics With Heart Failure:"Effect on Left Ventricular Function and Skeletal Muscle"
Study Start Date : September 2010
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: optimized diabetic control
each participant will be assigned to be optimized in a dedicated diabetic clinic
Other: all antidiabetic drugs will be appliable
We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%

No Intervention: control
participants will be assigned to follow what ever control they were in before the study and not to change any antidiabetic treatment during the interventions period.

Primary Outcome Measures :
  1. Left ventricular function [ Time Frame: 4 month ]

    Left ventricular function will be evaluated using echocardiografi measuring:

    - 2D Ejection fraction (using an ultrasound agent), global and regional tissue velocity, Strain / strain rate - all measures done during rest and dobutamin stress test.

Secondary Outcome Measures :
  1. hormonal and metabolic profile [ Time Frame: 4 month ]

  2. 6-minutes hall walk test [ Time Frame: 4 month ]
    using a hall walk protocol

  3. Exercise capacity and peak oxygen consumption [ Time Frame: 4 month ]
    using a treadmill test and continues oxygen consumption measurement

  4. Muscle strength and mass [ Time Frame: 4 month ]
    muscle strength: hand grip test

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ejection fraction =<45%
  • Diabetes
  • Hba1c =>7,5%
  • In anticongestive treatment
  • NYHA class 2-4

Exclusion Criteria:

  • Severe angina (CCS 3-4)
  • Hemodynamic significant heart valve disease
  • Congenital heart disease
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01213784

Layout table for location information
Dept. of cardiology, Aarhus university hospital Skejby
Aarhus, Region Midtjylland, Denmark, 8200
Sponsors and Collaborators
University of Aarhus
The Danish Diabetes Association
Layout table for investigator information
Principal Investigator: Roni R Nielsen, MD Dept. of cardiology, University hospital Aarhus Skejby
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Aarhus Identifier: NCT01213784    
Other Study ID Numbers: M20090047
First Posted: October 4, 2010    Key Record Dates
Last Update Posted: March 6, 2015
Last Verified: June 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Hypoglycemic Agents
Physiological Effects of Drugs